T-Cell Immunotherapies Targeting Histocompatibility and Tumor Antigens in Hematological Malignancies.

Frontiers in Immunology
Valérie JanelleJean-Sébastien Delisle

Abstract

Over the last decades, T-cell immunotherapy has revealed itself as a powerful, and often curative, strategy to treat blood cancers. In hematopoietic cell transplantation, most of the so-called graft-vs.-leukemia (GVL) effect hinges on the recognition of histocompatibility antigens that reflect immunologically relevant genetic variants between donors and recipients. Whether other variants acquired during the neoplastic transformation, or the aberrant expression of gene products can yield antigenic targets of similar relevance as the minor histocompatibility antigens is actively being pursued. Modern genomics and proteomics have enabled the high throughput identification of candidate antigens for immunotherapy in both autologous and allogeneic settings. As such, these major histocompatibility complex-associated tumor-specific (TSA) and tumor-associated antigens (TAA) can allow for the targeting of multiple blood neoplasms, which is a limitation for other immunotherapeutic approaches, such as chimeric antigen receptor (CAR)-modified T cells. We review the current strategies taken to translate these discoveries into T-cell therapies and propose how these could be introduced in clinical practice. Specifically, we discuss the criteri...Continue Reading

References

May 1, 1986·European Journal of Immunology·R A SherwoodL S Rayfield
Dec 21, 2002·Immunological Reviews·Derry RoopenianAaron Brown
Feb 26, 2003·Proceedings of the National Academy of Sciences of the United States of America·W A Erik MarijtJ H Frederik Falkenburg
May 4, 2004·Nature Reviews. Cancer·Marie Bleakley, Stanley R Riddell
Jun 28, 2005·Proceedings of the National Academy of Sciences of the United States of America·Christopher A KlebanoffNicholas P Restifo
Oct 18, 2005·Nature Medicine·Marie-Christine MeunierClaude Perreault
Jun 21, 2006·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Alison W LorenDavid L Porter
Feb 6, 2007·The Journal of Immunology : Official Journal of the American Association of Immunologists·Giorgio ParmianiChiara Castelli
Jul 6, 2007·Leukemia·J H Kessler, C J M Melief
Mar 14, 2009·Lancet·James L M FerraraErnst Holler
Apr 30, 2009·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Jason A DubovskyJavier A Pinilla-Ibarz
Jun 16, 2009·Nature Medicine·Luca GattinoniNicholas P Restifo
Nov 26, 2009·Nature Genetics·Steven A McCarrollDavid Altshuler
Feb 20, 2010·Nature Reviews. Cancer·Robert R Jenq, Marcel R M van den Brink
Apr 20, 2010·Nature Medicine·Gavin M BendleTon N M Schumacher
Jun 11, 2010·Proceedings of the National Academy of Sciences of the United States of America·Marleen M van LoenenMirjam H M Heemskerk
Jan 14, 2011·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·J H Frederik Falkenburg, Edus H Warren
Jul 8, 2011·Blood·Krystel VincentClaude Perreault
Sep 15, 2011·Molecular Therapy : the Journal of the American Society of Gene Therapy·Ulrike GerdemannAnn M Leen
Sep 20, 2011·Nature Medicine·Luca GattinoniNicholas P Restifo
Nov 4, 2011·The New England Journal of Medicine·Antonio Di StasiMalcolm K Brenner

❮ Previous
Next ❯

Citations

Nov 17, 2020·Frontiers in Immunology·Jason T WeinfurterMatthew R Reynolds
Jan 12, 2021·Frontiers in Cell and Developmental Biology·Patricia Castro-SanchezRose Zamoyska
Feb 19, 2021·International Journal of Cancer. Journal International Du Cancer·Junting MaBeixing Liu
Jul 22, 2021·Nanoscale Horizons : the Home for Rapid Reports of Exceptional Significance in Nanoscience and Nanotechnolgy·Seokhwan ChungMiqin Zhang

❮ Previous
Next ❯

Methods Mentioned

BETA
transgenic

Clinical Trials Mentioned

NCT03326921
NCT03091933
NCT02203903
NCT02494167
NCT02475707
NCT02291848
NCT01333046

Related Concepts

Related Feeds

Cancer Genomics (Keystone)

Cancer genomics approaches employ high-throughput technologies to identify the complete catalog of somatic alterations that characterize the genome, transcriptome and epigenome of cohorts of tumor samples. Discover the latest research using such technologies in this feed.